https://www.selleckchem.com/pr....oducts/lipofermata.h
%, RUS 3.5 % and ES 49.5 %; p 0.0001). If only patients without comorbidities are considered (200/60, statistically differences between countries persist in all preventive treatments. There is heterogeneity in the choice of preventive treatment between different countries. Prospective comparative studies of the different oral and subcutaneous alternatives would help to create a global therapeutic algorithm that would guarantee the best option for our patients. There is heterogeneity in the choice of preventive treatment betwe
Like
Comment
Share
